TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 194 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The firm is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The firm has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
Follow-Up Questions
What is the price performance of TCRX stock?
The current price of TCRX is $1.72, it has decreased 0% in the last trading day.
What are the primary business themes or industries for TScan Therapeutics Inc?
TScan Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is TScan Therapeutics Inc market cap?
TScan Therapeutics Inc's current market cap is $97.6M
Is TScan Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for TScan Therapeutics Inc, including 4 strong buy, 9 buy, 1 hold, 0 sell, and 4 strong sell
